Home » GPhA: State Biosimilar Laws Could Have ‘Chilling Effect’
GPhA: State Biosimilar Laws Could Have ‘Chilling Effect’
Brand drugmakers are pushing states to enact legislation that could create hurdles for biosimilar substitution — a business move designed to hold on to profits, GPhA says. Amgen and Genentech have been pushing state legislators to enact measures, including a bill currently making its way through Virginia’s General Assembly that could have a chilling effect on biosimilar substitution because it requires pharmacists to notify prescribers that an interchangeable biosimilar is being doled out to the patient, GPhA said.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May